Toggle Summary Oct 28, 2010
PRO-PHARMACEUTICALS SHIPS FIRST COMMERCIAL ORDER FOR DAVANAT®
South American Distributor PROCAPS S.A. To Market and Sell DAVANAT® in Colombia, South America
View HTML
Toggle Summary Sep 13, 2010
PRO-PHARMACEUTICALS COLLABORATES WITH NUMODA TO MANAGE PHASE lll CLINICAL TRIAL TO INCREASE SPEED-TO-MARKET FOR DAVANAT®
View HTML
Toggle Summary Sep 10, 2010
PRO-PHARMACEUTICALS' PRESENTATION AT RODMAN AND RENSHAW'S ANNUAL GLOBAL INVESTMENT CONFERENCE TO BE WEBCAST LIVE
View HTML
Toggle Summary Aug 24, 2010
PRO-PHARMACEUTICALS' EXECUTIVES TO PRESENT CORPORATE UPDATE AT THREE INVESTOR CONFERENCES IN SEPTEMBER
Rodman and Renshaw Annual Global Investment Conference; BioPharm America 2010 MassBio Investors Forum, and Accredited Members Fall 2010 Small/Micro Cap Conference
View HTML
Toggle Summary Aug 13, 2010
PRO-PHARMACEUTICALS REPORTS SECOND QUARTER 2010 AND SIX MONTHS FINANCIAL RESULTS
View HTML
Toggle Summary Jun 22, 2010
PRO-PHARMACEUTICALS RECEIVES FIRST COMMERCIAL ORDER FOR DAVANAT®
PROCAPS S.A. To Make Upfront Payment and Will Be Responsible for the Approval, Distribution, Marketing and Sales of DAVANAT® in Colombia
View HTML
Toggle Summary Jun 15, 2010
FORMER GLAXO SMITH KLINE CHIEF MEDICAL OFFICER PETER G. TRABER, M.D., NAMED CHIEF MEDICAL OFFICER OF PRO-PHARMACEUTICALS
Dr. Traber Will Lead Design of Phase lll Colorectal Cancer Trial for DAVANAT® and the Company's FDA Approval Strategy
View HTML
Toggle Summary May 24, 2010
PRO-PHARMACEUTICALS PREPARES PHASE III DAVANAT® TRIAL FOR SECOND HALF 2010
Peter G. Traber, M.D. Joins Trial Design Team to Finalize and Implement Strategy for FDA Approval
View HTML
Toggle Summary May 12, 2010
PRO-PHARMACEUTICALS REPORTS FIRST QUARTER 2010 FINANCIAL RESULTS
View HTML
Toggle Summary May 11, 2010
PRO-PHARMACEUTICALS CLOSES FINAL $570,000 TRANCHE FROM 10X FUND TO COMPLETE $6 MILLION RAISE
View HTML